Emisphere's eligen aids in human growth hormone absorption, data shows

By Elaine Rigoli

Tampa, Fla., Sept. 5 - Novartis Pharma AG has notified Emisphere Technologies, Inc. of new phase 1 data indicating that recombinant human growth hormone (rhGH) can be absorbed when given to growth hormone-deficient patients in a prototype oral formulation using Emisphere's eligen delivery technology.

In this small proof-of-concept study, eight growth hormone-deficient patients were given oral rhGH.

Novartis, a Basel, Switzerland, pharmaceutical company, investigated pharmacokinetics as well as the pharmacodynamic properties of the orally delivered rhGH. The study showed that growth hormone peaks were recorded in all patients at some time points, although with considerable variability and minor endogenous growth hormone interference.

Tarrytown, N.Y.-based biopharmaceutical company Emisphere said this study is the first to show that such a large and complex protein can be delivered orally in humans in an active form.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.